PPJS Health. Photo Description: Ricardo / JPNN
jpnn.com, Jakarta – Commemorating International Women’s Day every March 8 is a quick way to give voice to women’s aspirations.
Access to treatment for thousands of patients is no exception Breast cancer, Which is the most common type of cancer in women.
To date, breast cancer patients, especially those with early stage HER2 (Human Epidermal Growth Factor Receptor 2) positive, are still struggling for their treatment to be fully confirmed by the PPJS cation.
Although the regulations clearly state what treatments and medications are covered for PPJS injury, it is not certain that access to these treatments can actually be realized in practice.
Sardini (44), an advanced breast cancer patient from Yogakarta, faces this challenge.
Sardini had a bitter experience when he had to access treatment at PPJS as he implemented different policies in each region.
Sardini was diagnosed with HER2-positive stage 3 breast cancer in 2019 and was diagnosed with liver metastases last month. He recommended doctors for specific treatment for chemotherapy and thrombocytopenia.
While still in stage 3, Sardini admitted that he had received information that Trozuzumab could not claim ownership of the PPJS cassette because it was only available for the metastatic stage or stage 4.
–
